LAUSANNE, Switzerland--(BUSINESS WIRE)--Galderma today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to the investigational therapy nemolizumab for the treatment of pruritus associated with prurigo nodularis.
Dermatology company Galderma, which months ago secured the services of former Shire chief Flemming Ørnskov as CEO, on Monday scored the FDA’s breakthrough status for nemolizumab, a therapy under development to treat pruritus associated with prurigo nodularis, a rare chronic skin condition characterized by thick skin nodules covering large body areas.